Editorial BURRILL BERNARD CROHN (1884-1983): the MAN
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
An Overview of Crohn's Disease: an Explanation and Analysis of the Event Planning Process Claire Wilcox Grand Valley State University
Grand Valley State University ScholarWorks@GVSU Honors Projects Undergraduate Research and Creative Practice 4-25-2014 Chronically Ill but Chronically Fabulous: An Overview of Crohn's Disease: An Explanation and Analysis of the Event Planning Process Claire Wilcox Grand Valley State University Follow this and additional works at: http://scholarworks.gvsu.edu/honorsprojects Recommended Citation Wilcox, Claire, "Chronically Ill but Chronically Fabulous: An Overview of Crohn's Disease: An Explanation and Analysis of the Event Planning Process" (2014). Honors Projects. 318. http://scholarworks.gvsu.edu/honorsprojects/318 This Open Access is brought to you for free and open access by the Undergraduate Research and Creative Practice at ScholarWorks@GVSU. It has been accepted for inclusion in Honors Projects by an authorized administrator of ScholarWorks@GVSU. For more information, please contact [email protected]. Chronically Ill but Chronically Fabulous 1 Chronically Ill but Chronically Fabulous: An Overview of Crohn's Disease An Explanation and Analysis of the Event Planning Process Claire Wilcox Grand Valley State University HNR 499 Dr. J. Chamberlain Prof. Nelson Van Elderen April 25, 2014 Chronically Ill but Chronically Fabulous 2 Dedications I would like to thank, first and foremost, my Holy Father in Heaven. Without His constant guidance, provision, and healing I would not be where I am. It is through his power that I have been able to study abroad and succeed academically and socially in college. He walked with me through my physical and mental pain, lifted me up when it seemed impossible to go on, caught my tears in his cradled hands, and cheered me on through it all – simply fighting for his beloved child. -
An Empirical Model of Information System to Improve Performance Ability in Patients with Crohn’S Disease
International Journal of Control and Automation Vol.7, No.9 (2014), pp.305-316 http://dx.doi.org/10.14257/ijca.2014.7.9.27 An Empirical Model of Information System to Improve Performance Ability in Patients with Crohn’s Disease Seong-Ran Lee Department of Medical Information, Kongju National University [email protected] Abstract This paper is to develop an empirical model of information system to improve performance ability in patients with Crohn’s disease. The pairwise t-test was done to compare the before and after intervention effect of performance ability in patients with Crohn’s disease. The results of this findings are as follows. Firstly, comparing the mean scores in the stress status, respondents’ score(52.07±0.82) after intervention a statistically significantly decreased than respondents(76.25±1.49) before intervention(t=1.94, p=.026). Secondly, this paper found that the performance ability in patients with Crohn’s disease was increased by 68.92- 82.95% compared with the previous status. Therefore, this paper will provide framework of a system development for managing the patients with Crohn’s disease according to information system . Keywords: Empirical model, Information system, Performance ability, Crohn’s disease 1. Introduction Crohn’s disease is a type of inflammatory bowel disease that may affect any part of the gastrointestinal tract from mouth to anus. Symptoms often include: abdominal pain, diarrhea (which may be bloody if inflammation is severe), fever and weight loss, Other complications may occur outside the gastrointestinal tract and include: anemia, skin rashes, arthritis, inflammation of the eye, and tiredness. -
Comparison of the Rome IV Criteria with the Rome III Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care
This is a repository copy of Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/166989/ Version: Accepted Version Article: Black, CJ, Craig, O, Gracie, DJ et al. (1 more author) (2020) Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gut. ISSN 0017-5749 https://doi.org/10.1136/gutjnl-2020-322519 © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. This manuscript version is made available under the CC BY-NC 4.0 license https://creativecommons.org/licenses/by-nc/4.0/ Reuse This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative works on the same terms. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Black et al. Page 1 of 38 Accepted for publication 3rd September 2020 TITLE PAGE Title: Comparison of the Rome IV Criteria with the Rome III Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care. -
Redalyc.Crohn Disease
Autopsy and Case Reports E-ISSN: 2236-1960 [email protected] Hospital Universitário da Universidade de São Paulo Brasil Geller, Stephen A.; de Campos, Fernando P. F. Crohn disease Autopsy and Case Reports, vol. 5, núm. 2, abril-junio, 2015, pp. 5-8 Hospital Universitário da Universidade de São Paulo São Paulo, Brasil Available in: http://www.redalyc.org/articulo.oa?id=576060829002 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Image in focus Imagem em foco Crohn disease Stephen A Gellerab, Fernando P F de Camposc Geller SA, Campos FPF. Crohn disease. Autopsy Case Rep [Internet]. 2015; 5(2):5-8. http://dx.doi.org/10.4322/acr.2015.001 Dr. Stephen A Geller personal archive Aretaeus of Cappadocia (1st century CE) described patient dying after a prolonged dysentery-like course. a young man with chronic and recurring abdominal Louis XIII, King of France (1601-1643) died at the age distress possibly representing the first recorded instance of 42 after decades of abdominal pain, fever, bloody of Crohn disease (CD).1-3 More evidence that this disease diarrhea and rectal/perianal abscesses.4 However, it was was extant for many years comes from the description in 1761 that Giovanni Battista Morgagni (1682-1771), of the 10th century English king, Alfred “the great,” a towering figure in the history of medicine, described who suffered for many years from what was a typical a 20-year-old man with typical regional ileitis, who enteritis but also had anal fistula and/or abscess.4 In died. -
Umb 3 Lat Umb2'2006 Corectat3.Qxd
Archives of the Balkan Medical Union vol. 50, no. 3, pp. 399-405 Copyright © 2015 CELSIUS September 2015 REVIEW THE GENESIS OF INFLAMMATORY BOWEL DISEASE YESTERDAY, TODAY, TOMORROW DORINA CALAGIU1, MIRCEA DICULESCU1,2, ROXANA MARIA NEMEÆ3, CORINA SILVIA POP1,4 1„Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania 2Gastroenterology and Hepatology Center, Fundeni Clincal Insitute, Bucharest, Romania 3”Marius Nasta” Institute National of Pneumology, Bucharest, Romania 4Emergency University Hospital, Bucharest, Romania SUMMARY RÉSUMÉ The discovery of Inflammatory Bowel Disease (IBD) has had a La genèse de la maladie inflammatoire de l’intestin hier, à tumultuous trajectory, beginning with its recognition as a medical présent, demain entity to defining and understanding. The genesis of the two diseases included in the spectrum of IBD is the same with the La découverte de la maladie inflammatoire de l'intestin (MII) a eu one of humanity, the earliest descriptions belonging to ancient une trajectoire tumultueuse, en commençant par sa reconnais- Greeks, but the differentiation between them and other intestinal sance comme une entité médicale à la définition et la pathologies took place years later. Even establishing the names of compréhension. La genèse de ces deux maladies incluses dans le Ulcerative colitis (UC) and Crohn’s disease (CD) encountered spectre de l'IBD est la même avec celle de l'humanité, les difficulties. With the beginning of the modern era, remarkable premières descriptions appartenant aux Grecs anciens, mais la progress has been made in the field of medicine - both in under- différenciation entre eux et d'autres pathologies intestinales a eu standing the diseases and in treating it. -
Own Your Treatment
IBD OWN YOUR TREATMENT INFLAMMATORY INFORMATION FOR BOWEL DISEASE PATIENTS This document is only intended for use by a personA after their healthcare professional has made the decision to treat them with Entyvio® subcutaneous (SC) HOW CAN I PREPARE TO SELF-INJECT?W GETTING STARTED WITH ENTYVIO® (VEDOLIZUMAB) This booklet is for people who have recently been prescribed Entyvio® for subcutaneous (SC) injection. If you don’t really know what this means, that’s okay. We’re about to give you an overview of what you need to know about your treatment. Don’t worry if it seems like a lot to get to grips with – we’ll be here to help every step of the way. Let’s get started. B Contents 2 About Entyvio® 1 What is Entyvio®? 2 How does Entyvio® work? 8 What can I expect from Entyvio® treatment? 10 Does Entyvio® cause side effects? 13 3 Using Entyvio® 15 Your treatment schedule 16 How can I prepare to self-inject? 22 How do I use the Entyvio® pen? 26 How do I use the Entyvio® syringe? 30 Why should I rehearse with a practice device? 35 4 Living with inflammatory bowel disease 40 Your diet 41 Keeping active 43 Your support network 45 Talking about your health 46 5 Glossary 51 ABOUT ENTYVIO® 1 WHAT IS ENTYVIO®? Entyvio® is a treatment for adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD).1 It belongs to a group of treatments called biologics. Biologics are called this because they’re made through a process that involves living organisms rather than a chemical process. -
Ulcerative Colitis and Crohn Disease in Cuban Pediatric Patients
MedDocs Publishers ISSN: 2637-4501 Annals of Gastroenterology and the Digestive System Open Access | Research Article Ulcerative Colitis and Crohn Disease in Cuban Pediatric Patients Yamila del Carmen Velazco-Villaurrutia1*; Elsa Francisca García-Bacallao1; Idalmis Aguilera-Matos1; Sarah Esther Díaz-Oliva1; Alfredo Hierro González1; Licet González Fabian2; Liana Margarita Labrada Moreno3 1Department of Pediatric Gastroenterology, University of Medical Sciences of Havana, Institute of Gastroenterology, Havana, Cuba. 2Department of Pathological Anatomy, University of Medical Sciences of Havana. Institute of Gastroenterology, Havana, Cuba. 3Biostatistics Department, University of Medical Sciences of Havana, Institute of Gastroenterology, Havana Cuba. *Corresponding Author(s): Yamila del Carmen Abstract Velazco Villaurrutia Introduction: Inflammatory bowel disease includes ul- Department of Pediatric Gastroenterology, University cerative colitis and Crohn Disease (CD). About 25-30% of diagnosed patients correspond to pediatric age, with an in- of Medical Sciences of Havana, Institute of Gastroen- creasing prevalence. terology, Havana, Cuba. Email: [email protected] Objective:To characterize children with ulcerative colitis and Crohn disease. Material and Method: A descriptive cross-sectional study was carried out that included 31 children with con- firmed diagnoses of both entities according to the Lennard- Received: Jul 09, 2020 Jones criteria, attended in the pediatric consultation of the Accepted: Oct 01, 2020 Institute of Gastroenterology between 2017 and 2019. The variables were measured: age, sex, clinical manifestations, Published Online: Oct 05, 2020 location, endoscopic and histological signs when diagnosing Journal: Annals of Gastroenterology and the Digestive System the disease and the current humoral immune response. Publisher: MedDocs Publishers LLC Results: A higher proportion of colitis (61.3%) than Online edition: http://meddocsonline.org/ Cohn’s disease (38.7%) was observed, but in the latter there Copyright: © Velazco-Villaurrutia YC (2020). -
Acute Febrile Neutrophilic Dermatosis in a Patient with Crohn's Disease
Acta Dermatovenerologica 2018;27:161-163 Acta Dermatovenerol APA Alpina, Pannonica et Adriatica doi: 10.15570/actaapa.2018.34 Acute febrile neutrophilic dermatosis in a patient with Crohn’s disease: case report and review of the literature Pavel Skok1 ✉, Kristijan Skok2 Abstract Crohn’s disease is a chronic inflammatory bowel disease. The disease is characterized by acute exacerbations with diarrhea, abdominal pain, fever, anorexia, intestinal bleeding, and weight loss. Immune-mediated diseases that are frequently associated with Crohn’s disease include arthritis, ankylosing spondylitis, sacroiliitis, episcleritis, uveitis, and skin lesions, such as erythema nodosum and pyoderma gangrenosum. The authors present the case of a 22-year-old female patient that was admitted to their hospital due to diarrhea, fever, arthralgias, and diffuse erythematous papules and plaques with vesicles and pustules affecting the patient’s face, lips, arms, trunk, and legs. Six months prior to onset, the patient was diagnosed with terminal ileitis and Crohn’s disease of the sigmoid colon. Treatment with mesalazine and budesonide had been introduced. In the diagnostic procedure, a skin biopsy was taken from the patient. Histology confirmed dense infiltration of neutrophilic polymorphonuclear leukocytes, or Sweet’s syndrome. This condition is a rare manifestation of chronic inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis. This syndrome is thought to be a hypersensitivity reaction and may be associated with various inflammatory, infectious, -
Understanding Crohn's Disease
Understanding By Jim Trageser Croh n’s Disease WITHOUT A CLEAR understanding of its underlying causes, • Ileocolitis: This is the most common type, which affects the a cure or even a single test to make a diagnosis, Crohn’s disease ileum, occurring in approximately 45 percent of Crohn’s patients. remains a baffling chronic illness that presents many primary • Ileitis: This type, occurring in approximately 30 percent of immunodeficiency patients and their physicians with an ongoing Crohn’s patients, also affects the ileum, but it is more severe and set of challenges for addressing its significant health risks. This can lead to the formation of abscesses or fistulas, or abnormal inflammatory bowel disease (IBD) initially manifests as gastroin - tubes between the intestines and the abdomen or skin. testinal (GI) distress, but it can progress to life-threatening • Granulomatous: One-fifth of all Crohn’s patients have this type, blockages and ulcers, requiring emergency surgical intervention. affecting the main part of the large intestine, including the sigmoid. Even in the majority of cases, when patients enjoy long periods • Gastroduodenal: This relatively rare type affects the area of remission, Crohn’s requires constant monitoring and persistent between the stomach and the small intestine, affecting only dietary and lifestyle changes that demand close cooperation about 5 percent of patients. between patients and their physicians. • Jejunoileitis: The remaining 5 percent of patients develop this type, which affects the main part of the small intestine. What Is Crohn’s Disease? Crohn’s generally manifests in the late teens or 20s, although Crohn’s was first described as a specific subset of IBD in a it can appear at any age. -
An Investigation Into the Role of Optineurin in Macrophage-Mediated Acute Antibacterial Response in Inflammatory Bowel Disease
An investigation into the role of optineurin in macrophage-mediated acute antibacterial response in inflammatory bowel disease By Thean Soon Chew A thesis submitted to UCL for the degree of Doctor of Philosophy Division of Medicine 2015 1 I, Thean Soon Chew confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. 2 ex nihilo nihil fit 3 Abstract Crohn’s disease (CD) is now recognised to be due to defective host responses to bacteria in genetically susceptible individuals. Others in our research group previously found defective neutrophil recruitment, bacterial clearance and monocyte-derived macrophage (MDM) proinflammatory cytokine secretion in CD. To investigate the defective cytokine secretion, we performed transcriptomic analysis and identified reduced MDM optineurin (OPTN) expression in 10% CD patients. Here, I show that macrophages stimulated with E. coli, bacterial Toll-like and NOD-like receptor ligands upregulate OPTN, a Golgi complex protein that regulates vesicle transport. In vitro, Optn-/- bone marrow-derived macrophages (BMDM) stimulated with E. coli secrete significantly lower levels of proinflammatory TNF and IL6 cytokines, which is normalised to wildtype levels on addition of lysosomal function inhibitors. In vivo, Optn-/- mice develop a more severe Citrobacter colitis with greater mortality, an early defective neutrophil recruitment to the bowel and lower levels of serum proinflammatory cytokines. The Optn-/- mice also demonstrated a similar phenotype of defective neutrophil recruitment and lower serum proinflammatory cytokines in an E. coli-induced peritonitis. These results indicate that the low OPTN expression originally identified in CD macrophages has likely contributed to an attenuated antibacterial response, which potentially led to the development of bowel inflammation. -
Moftah Hussin Alhagamhmad
Discovering the mechanism of action of nutritional therapy and evolving an innovative formula for the treatment of Crohn’s disease A thesis in fulfilment of the requirements for the degree of Doctor of Philosophy Moftah Hussin Alhagamhmad School of Women’s and Children’s health Faculty of Medicine The University of New South Wales August 2015 Table of contents List of abbreviations …………………………………………………………………………………………..V List of Figures……………………………………………………………………………………………...... IX List of Tables…………………………………………………………………………………………….......XII Publications………………………………………………………………………………………………....XIII Acknowledgements........................................................................................................................................XIV Chapter 1: Literature review and aims 1.1 Background and disease discovery………………………………………………………………………..1 1.2 Epidemiology…………………………………………………………………………………………..….2 1.3 Pathophysiology of Crohn’s disease 1.3.1 Alteration in the immune response…………………………………………………………….….6 1.3.2 Role of bacteria…………………………………………………………………………………..13 1.3.3 Role of genetics………………………………………………………………………………….26 1.3.4 Role of environmental factors…………………………………………………………………...28 1.4 Diagnosis of Crohn’s disease 1.4.1 History and clinical examination………………………………………………………………..33 1.4.2 Laboratory findings……………………………………………………………………………..33 1.4.3 Imaging studies& endoscopic evaluation……………………………………………………….34 1.4.4 Crohn’s disease activity index…………………………………………………………………...34 1.5 Symptomatology of Crohn’s disease 1.5.1 Intestinal Manifestations…………………………………………………………………………36 -
Investigations of Irgm1 During Experimental Infections with Mycobacterium Avium Paratuberculosis
Investigations of Irgm1 during experimental infections with Mycobacterium avium paratuberculosis Louis Kreitmann Laboratory of Dr. Marcel Behr Department of Experimental Medicine McGill University Montreal, Quebec, Canada December 2013 A thesis submitted to McGill University in partial fulfilment of the requirements of the degree of Master of Science © Louis Kreitmann 2013 1 This work is dedicated to my mice. 2 Table of Contents Abstract..................................................................................................................................5 Résumé..................................................................................................................................6 Acknowledgements..............................................................................................................8 List of abbreviations...........................................................................................................12 1) Introduction and review of the literature.....................................................................14 1.1) Mycobacterium avium ssp. paratuberculosis...........................................................14 1.2) Johne's disease........................................................................................................18 1.2.1) Historical background......................................................................................18 1.2.2) Epidemiology....................................................................................................19